Interferon-λ3 polymorphisms in pegylated-interferon-α plus ribavirin therapy for genotype-2 chronic hepatitis C

Table 1 Analysis of factors affecting rapid virologic response to pegylated interferon-α plus ribavirin combination therapy in patients infected with hepatitis C virus genotype 2

	RVR	non-RVR	RVR vs non-RVR (1: non-RVR/2: RVR)
			Univariate analysis	Multivariate analysis
			P value	OR	95%CI	P value
Baseline factors
Demographic data
Number of patients	111	69
Gender (1:male/2:female)	54/57	31/38	0.8705
Age (yr)	60 (18-76)	60 (18-80)	0.9623
Body weight (kg)	59.4 (35.6-90.9)	56.0 (37.0-104)	0.5154
Body mass index (kg/m2)	23.4 (17.1-31.2)	22.8 (15.2-34.8)	0.9645
Histological fibrosis of liver (F0/1/2/3/4/ND )1	5/45/18/13/13/17	2/24/9/6/17/11
(F0-3/F4)	81/13	41/17	0.0202
Prior interferon and ribavirin treatment response
Naïve/Relapse/Non response	101/10/0	64/3/2	0.8577
Laboratory data
Genetic variation at rs8099917 (TT/TG or GG)	87/24	55/14	0.9800
HCV-RNA (log10IU/mL)	5.5 (5.0-7.0)	6.4 (5.0-7.3)	< 0.0001	4.40	2.24-8.63 (per 1.0 log10IU/mL)	< 0.0001
HCV Genotype (2a/2b/2a + 2b/ND)	69/23/2/17	29/34/2/4	0.0005
White blood cells (/μL)	4800 (2400-10300)	4700 (2000-10200)	0.5170
Hemoglobin (g/dL)	14.1(9.5-18.2)	13.8 (9.3-16.9)	0.1899
Platelets (× 104/μL)	17.1 (4.8-34.1)	16.6 (5.5-34.1)	0.7993
Aspartate aminotransferase (IU/L)	48 (16-317)	48 (13-455)	0.6753
Alanine aminotransferase (IU/L)	57 (10-361)	56 (9-356)	0.9699
Gamma-glutamyl-transpeptitase (IU/L)	43 (7-719)	48 (9-331)	0.7526
Albumin (g/dL)	4.1 (3.2-5.0)	4.0 (2.9-4.8)	0.0029	0.13	0.04-0.42 (per 1.0 g/dL)	0.0006
Fasting total cholesterol (mg/dL)	170 (118-265)	173 (106-270)	0.8155
Fasting low density lipoprotein-cholesterol (mg/dL)	99 (45-158)	103 (40-181)	0.4186
Fasting plasma glucose (mg/dL)	99 (76-221)	100 (76-320)	0.2002
Homeostasis model assessment-Insulin Resistance	1.59 (0.56-10.83)	1.38 (0.79-6.88)	0.4722
Alpha-fetoprotein (ng/mL)	4.7 (1.6-193.6)	5.0 (1.0-130)	0.4101

¹Classified by METAVIR score. Data are expressed as number of patients or median (range); ND: Not done; HCV: Hepatitis C virus; RVR: Rapid virologic response.

Table 2 Analysis of factors affecting sustained virologic response in non-rapid virologic response hepatitis C virus genotype 2 patients treated with 36 or 48-wk pegylated interferon-α plus ribavirin combination therapy

	SVR	non-SVR	SVR vs non-SVR (1: non-SVR/2: SVR)
			Univaritate analysis	Multivaritate analysis
			P value	OR	95%CI	P value
Baseline factors
Demographic data
Number of patients	50	19
Gender (1:male/2:female)	20/30	11/8	0.2873
Age (yr)	60.5 (18-80)	53 (39-73)	0.2341
Body weight (kg)	55.0 (37.0-101.0)	64.0 (44.0-104.0)	0.1563
Body mass index (kg/m2)	22.8 (15.2-32.8)	22.8 (18.8-34.8)	0.2426
Histological fibrosis of liver (F0/1/2/3/4/ND)1	1/18/6/6/10/9	1/6/3/0/7/2
(F0-3/F4)	31/10	10/7	0.2050
Prior interferon and ribavirin treatment response
Naïve/Relapse/Non response	46/3/1	18/0/1	0.8933
Laboratory data
Genetic variation at rs8099917 (TG or GG/TT)	6/44	8/11	0.0146	5.87 (1; TG or GG/ 2; TT)	1.62-21.22	0.0059
HCV-RNA (Log10IU/mL)	6.3 (5.0-7.3)	6.4 (5.0-7.2)	0.6064
HCV Genotype (2a/2b/2a + 2b/ND)	21/24/2/3	8/10/0/1	0.8156
White blood cells (/μL)	4700 (2800-7800)	5550 (2000-10200)	0.3001
Hemoglobin (g/dL)	13.8 (11.0-16.9)	13.75 (11.0-16.8)	0.9279
Platelets (× 104/μL)	16.6 (6.0-34.1)	16.55 (6.1-29.7)	0.9834
Aspartate aminotransferase (IU/L)	54 (15-455)	32 (13-264)	0.0751
Alanine aminotransferase (IU/L)	59 (12-356)	36.5 (9-231)	0.1866
Gamma-glutamyl-transpeptitase (IU/L)	49 (9-292)	47 (11-331)	0.9237
Albumin (g/dL)	4.0 (2.9-4.8)	3.9 (3.1-4.7)	0.5738
Fasting total cholesterol (mg/dL)	172 (108-256)	178 (106-270)	0.6894
Fasting low density lipoprotein-cholesterol (mg/dL)	102 (54-177)	110 (40-181)	0.9647
Fasting plasma glucose (mg/dL)	98.5 (76-320)	103.5 (93-158)	0.1554
Homeostasis model assessment-Insulin Resistance	1.36 (0.78-6.78)	1.44 (1.19-5.39)	0.3151
Alpha-fetoprotein (ng/mL)	5.0 (1.0-96.0)	5.0 (2.0-130)	0.8593
On-treatment factors
Treatment
Adherence of Peg-IFN (%)2	77.1 (62.5-100.0)	91.4 (66.0-104.6)	0.0936
Adherence of RBV (%)2	75.0 (56.8-100.0)	86.1 (86.1-94.4)	0.0457
Duration of treatment (wk)	37 (36-48)	48 (36-48)	0.1449

¹Classified by METAVIR score;

²Calculated on the basis of 48-wk treatment. Note: Data are expressed as number of patients or median (range); ND: Not done; SVR: Sustained virologic response; HCV: Hepatitis C virus; Peg-IFN: Pegylated interferon; RBV: Ribavirin.